SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, announced today that it has delivered a BSD-2000 Hyperthermia System (BSD-2000) to Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (WRMC), located in Goodyear, Ariz. WRMC serves the western United States, including the major metropolitan areas of Phoenix, Denver, Los Angeles, Las Vegas, Seattle, Portland and Albuquerque. This is the eighth BSD Hyperthermia system purchased by CTCA®.
WRMC is a state-of-the-art, all-digital cancer hospital that provides advanced cancer treatments, world-class technologies and integrative therapies under one roof. The 213,000-square-foot facility is located on a 25-acre site, which is part of the Phoenix metropolitan area. Like the other CTCA cancer hospitals, WRMC provides the most advanced therapeutic resources in cancer treatment (http://www.cancercenter.com/western-hospital/about-western/history.cfm).
CTCA is a network of hospitals and one of the premier providers of cancer care in the world. CTCA physicians specialize in treating many types of cancer, including complex and advanced stage cases. “As the Medical Director of the Department of Radiation Oncology at the Cancer Treatment Centers of America in suburban Phoenix, Ariz., I am absolutely excited to be able to evolve our cancer therapeutics and research sophistication and capabilities with the advent of deep tissue hyperthermia,” said Dr. Lanceford M. Chong. “Our robust and multidisciplinary clinical protocols will allow us to partner with other academic institutions as we, together, evolve patient care and further oncologic knowledge, as well as explore the next frontier of cancer medicine in our unified and determined quest to conquer cancer!”
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.
